Nitasha Sarswat
Nitasha Sarswat is an expert in Cardiology at University of Chicago (United States). As of October 2026, ScienceLeadR ranks Nitasha Sarswat in the top 1% of experts worldwide for Cardiomyopathies and Proteostasis Deficiencies. Nitasha Sarswat has authored 343 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 2 of them ongoing. SLR score: 952 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Hematology - Transplantation - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 343
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Efficacy and Safety of ACEi, ARB, and ARNi in Cardiac Amyloidosis: A Retrospective Propensity Score-Matched Cohort Study. PMID 42800493 — hyperkalemia, mortality, receptors, angiotensin, safety, hospitalization, cohort studies, propensity score, cardiology, angiotensins, amyloidosis, sex, hypotension, therapeutics, amyloid, dizziness | Curr Probl Cardiol | 2026 | 0 |
| Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis. PMID 42696041 — bone marrow, biopsy, amyloidosis, immunoglobulin light-chain amyloidosis, hematologic diseases | Blood Adv | 2026 | 0 |
| Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. PMID 42669902 — mortality, heart diseases, prealbumin, natriuretic peptides, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy | J Am Heart Assoc | 2026 | 0 |
| Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM. PMID 42669031 — mortality, heart failure, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy | Eur J Heart Fail | 2026 | 0 |
| Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B. PMID 42669070 — mortality, heart failure, heart, prealbumin, cardiology, amyloidosis, therapeutics, outpatients, cardiomyopathies, transthyretin amyloidosis | J Am Coll Cardiol | 2026 | 1 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Open Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants NCT04988386 — amyloid neuropathies, safety, prealbumin, amyloid, cardiomyopathies, amyloid neuropathies, familial, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | Phase 3 | Active not recruiting | 2021 |
| Open label Extension Study to Evaluate the Long term Safety and Tolerability of Aficamten in Adults With HCM NCT04848506 — safety, tablets, maintenance, cardiomyopathy, hypertrophic, research, therapeutics, forests, cardiomyopathies | Phase 2/Phase 3 | Enrolling by invitation | 2021 |
LeadR Networks
Main global connection map